Literature DB >> 24661093

α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.

Michael J Marks1, Sharon R Grady, Outi Salminen, Miranda A Paley, Charles R Wageman, J Michael McIntosh, Paul Whiteaker.   

Abstract

Nicotinic acetylcholine receptors (nAChR) of the α6β2* subtype (where *indicates the possible presence of additional subunits) are prominently expressed on dopaminergic neurons. Because of this, their role in tobacco use and nicotine dependence has received much attention. Previous studies have demonstrated that α6β2*-nAChR are down-regulated following chronic nicotine exposure (unlike other subtypes that have been investigated - most prominently α4β2* nAChR). This study examines, for the first time, effects across a comprehensive chronic nicotine dose range. Chronic nicotine dose-responses and quantitative ligand-binding autoradiography were used to define nicotine sensitivity of changes in α4β2*-nAChR and α6β2*-nAChR expression. α6β2*-nAChR down-regulation by chronic nicotine exposure in dopaminergic and optic-tract nuclei was ≈three-fold more sensitive than up-regulation of α4β2*-nAChR. In contrast, nAChR-mediated [(3) H]-dopamine release from dopamine-terminal region synaptosomal preparations changed only in response to chronic treatment with high nicotine doses, whereas dopaminergic parameters (transporter expression and activity, dopamine receptor expression) were largely unchanged. Functional measures in olfactory tubercle preparations were made for the first time; both nAChR expression levels and nAChR-mediated functional measures changed differently between striatum and olfactory tubercles. These results show that functional changes measured using synaptosomal [(3) H]-DA release are primarily owing to changes in nAChR, rather than in dopaminergic, function. This study examined dose-response relationships for murine α6β2*-nicotinic acetylcholine receptor (nAChR) down-regulation by chronic nicotine treatment. The ID50 value for α6β2* down-regulation (35 nM) is ≈ 3x lower than the ED50 value for α4β2* nAChR up-regulation (95 nM), both well within the range reached by human smokers. Chronic nicotine treatment altered α6β2*- and α4β2*-nAChR-mediated [(3) H]-dopamine release from striatal and olfactory tubercle synaptosomes, but dopaminergic parameters were largely unaffected. We conclude that functional changes are primarily driven by altered nAChR activity.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  dopamine receptor; dopamine transporter; dopaminergic terminal regions; nicotinic receptor; α4β2 subtype

Mesh:

Substances:

Year:  2014        PMID: 24661093      PMCID: PMC4107044          DOI: 10.1111/jnc.12721

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  51 in total

1.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Authors:  Raad Nashmi; Cheng Xiao; Purnima Deshpande; Sheri McKinney; Sharon R Grady; Paul Whiteaker; Qi Huang; Tristan McClure-Begley; Jon M Lindstrom; Cesar Labarca; Allan C Collins; Michael J Marks; Henry A Lester
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

2.  Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration.

Authors:  Iris Jacobs; David J Anderson; Carol S Surowy; Pamela S Puttfarcken
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

3.  Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain.

Authors:  Michael J Marks; Tristan D McClure-Begley; Paul Whiteaker; Outi Salminen; Robert W B Brown; John Cooper; Allan C Collins; Jon M Lindstrom
Journal:  J Pharmacol Exp Ther       Date:  2011-01-12       Impact factor: 4.030

4.  Nicotine blood levels and subjective craving for cigarettes.

Authors:  M E Jarvik; D C Madsen; R E Olmstead; P N Iwamoto-Schaap; J L Elins; N L Benowitz
Journal:  Pharmacol Biochem Behav       Date:  2000-07       Impact factor: 3.533

5.  Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens.

Authors:  Lifen Zhang; Yu Dong; William M Doyon; John A Dani
Journal:  Biol Psychiatry       Date:  2011-08-27       Impact factor: 13.382

6.  Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.

Authors:  Cecilia Gotti; Milena Moretti; Francesco Clementi; Loredana Riganti; J Michael McIntosh; Allan C Collins; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

Review 7.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

8.  Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

9.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice.

Authors:  Outi Salminen; Jennifer A Drapeau; J Michael McIntosh; Allan C Collins; Michael J Marks; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2007-03-06       Impact factor: 4.436

View more
  16 in total

1.  The nicotine metabolite, cotinine, alters the assembly and trafficking of a subset of nicotinic acetylcholine receptors.

Authors:  Ashley M Fox; Faruk H Moonschi; Christopher I Richards
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

2.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

Review 3.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

4.  Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Authors:  Paula L Vieira-Brock; Lisa M McFadden; Shannon M Nielsen; Jonathan D Ellis; Elliot T Walters; Kristen A Stout; J Michael McIntosh; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2015-09-21       Impact factor: 4.030

Review 5.  The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.

Authors:  Hans Rollema; Raymond S Hurst
Journal:  Psychopharmacology (Berl)       Date:  2018-07-07       Impact factor: 4.530

6.  Chronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.

Authors:  Jessica L Koranda; Anne C Krok; Jian Xu; Anis Contractor; Daniel S McGehee; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurosci       Date:  2016-05-11       Impact factor: 6.167

7.  Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.

Authors:  Michael J Marks; Heidi C O'Neill; Kelly M Wynalda-Camozzi; Nick C Ortiz; Emily E Simmons; Caitlin A Short; Christopher M Butt; J Michael McIntosh; Sharon R Grady
Journal:  Neuropharmacology       Date:  2015-07-17       Impact factor: 5.250

8.  Nicotinic Acetylcholine Receptors as Targets for Tobacco Cessation Therapeutics: Cutting-Edge Methodologies to Understand Receptor Assembly and Trafficking.

Authors:  Ashley M Fox-Loe; Linda P Dwoskin; Christopher I Richards
Journal:  Neuromethods       Date:  2016-09-30

9.  r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.

Authors:  Joshua S Beckmann; Andrew C Meyer; M Pivavarchyk; David B Horton; Guangrong Zheng; Andrew M Smith; Thomas E Wooters; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

Review 10.  Crucial roles of the CHRNB3-CHRNA6 gene cluster on chromosome 8 in nicotine dependence: update and subjects for future research.

Authors:  L Wen; Z Yang; W Cui; M D Li
Journal:  Transl Psychiatry       Date:  2016-06-21       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.